Taxol induces bcl-2 phosphorylation and death of prostate cancer cells.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 8640809.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatment of prostate cancer cell lines expressing bcl-2 with taxol induces bcl-2 phosphorylation and programmed cell death, whereas treatment of bcl-2-negative prostate cancer cells with taxol does not induce apoptosis. bcl-2 phosphorylation seems to inhibit its binding to bax since less bax was observed in immunocomplex with bcl-2 in taxol-treated cancer cells. These findings support the use of the anticancer drug taxol for the treatment of bcl-2-positive prostate cancers and other bcl-2-positive malignancies, such as follicular lymphoma.
Medical subject headings
- Antineoplastic Agents, Phytogenic
- Apoptosis
- Neoplasm Proteins
- Paclitaxel
- Prostatic Neoplasms
- Proto-Oncogene Proteins